India  

Three doses of Pfizer vaccine can 'neutralise' Omicron variant, lab test shows

Sky News Wednesday, 8 December 2021
Three doses of Pfizer vaccine can 'neutralise' Omicron variant, lab test showsThree shots of the Pfizer/BioNTech COVID-19 vaccine has been shown to generate a neutralising effect against the new Omicron variant in a laboratory test.
0
shares
ShareTweetSavePostSend
 
Video Credit: Wibbitz Top Stories - Published
News video: Pfizer Says Its Booster Provides Protection Against Omicron Variant

Pfizer Says Its Booster Provides Protection Against Omicron Variant 01:30

Pfizer Says Its Booster Provides , Protection Against Omicron Variant. Pfizer Says Its Booster Provides , Protection Against Omicron Variant. NBC News reports officials with Pfizer-BioNTech say a booster dose of the companies' coronavirus vaccine supplies ample protection against the new Omicron...

💡 newsR Knowledge: Other News Mentions

Pfizer Pfizer American multinational pharmaceutical corporation

Pfizer's First Quarter Profits Blast Past 2022 Forecast [Video]

Pfizer's First Quarter Profits Blast Past 2022 Forecast

Pfizer's First Quarter , Profits Blast Past, 2022 Forecast. ABC reports that Pfizer's COVID-19 vaccine and treatment sales helped propel the pharmaceuticals company beyond Wall Street's first quarter expectations. . Pfizer's coronavirus vaccine Comirnaty raked in over $13 billion in sales for the first quarter. . Pfizer's coronavirus vaccine Comirnaty raked in over $13 billion in sales for the first quarter. . The vaccine has remained Pfizer's top selling product for almost the last year. . The drugmaker's pill treatment Paxloid reportedly added an additional $1.5 billion to the company's sales. . ABC reports that Pfizer's, profits grew 61% , in the first quarter. . On May 3, the company posted a net income of $7.86 billion and first quarter adjusted earnings of $1.62 per share. . The results easily exceeded the $1.49 increase predicted by industry analysts. . Compared to the same time last year, the company's revenue skyrocketed 77% , to reach $25.66 billion. . According to ABC, the drugmaker expects the company's total revenue in 2022 to reach between $98 billion and $102 billion. . Pfizer's COVID vaccine launched late in 2020 and quickly became the company's top selling product by the second quarter of 2021. In December of 2021, Pfizer's stock reached an all-time high of $61.71 per share.

Credit: Wibbitz Top Stories    Duration: 01:31Published
Biden Administration Secures 20 Million Courses of Paxlovid [Video]

Biden Administration Secures 20 Million Courses of Paxlovid

Biden Administration Secures , 20 Million Courses of Paxlovid. Biden Administration Secures , 20 Million Courses of Paxlovid. CNN reports that on April 25, a senior administration official said , 20 million treatment courses of Pfizer's antiviral COVID pill have been secured for the United States to purchase. 100,000 treatment courses will be provided to pharmacies per quarter as need and uptake are observed. . A treatment course of Paxlovid consists of taking three pills twice a day for five days. CNN reports that Pfizer released data last year showing that its antiviral COVID pill reduced the risk of hospitalization or death by 89% if taken within a few day of exhibiting symptoms. Paxlovid first became authorized by the FDA at the end of December. And there were very, very few pills around. The administration worked incredibly hard to both increase production and acquisition, and the good news is we’ve made really substantial progress, Dr. Ashish Jha, White House COVID-19 Response Coordinator, to NPR. Now we’ve got to turn those pills into prescriptions and into the things that patients can get so that they can get better if they get infected. We have a big set of efforts that we have been working on and launching, and we’re going to be doing a lot more this week, Dr. Ashish Jha, White House COVID-19 Response Coordinator, to NPR. On April 26, the administration is expected to announce expanded access to the pills via its federal antiviral pharmacy program. It is estimated that over 30,000 locations may provide free treatments in the future through the test-to-treat initiative. While the purchase of a significant amount of treatment courses has been secured thus far. CNN reports that the administration "will not be able to purchase more" unless it secures further funding from Congress

Credit: Wibbitz Top Stories    Duration: 01:30Published
Moderna Working on Vaccine Booster That Targets the Omicron Variant [Video]

Moderna Working on Vaccine Booster That Targets the Omicron Variant

Moderna Working on , Vaccine Booster That Targets, the Omicron Variant. The Associated Press reports that Moderna is developing an updated COVID-19 booster that offers protection against the omicron variant. On April 19, the pharmaceutical company released data suggesting that work on the updated booster was making progress. Prior to the emergence of omicron, Moderna had been developing a booster with added protection against the beta variant of coronavirus. According to the company, people who received that specific booster produced more antibodies capable of fighting a number of variants. AP reports that the omicron variant is able to more easily slip past the immune system's defenses than the original coronavirus. According to health officials, distributing boosters every few months does not present a practical solution to the mutating virus. As a result, Moderna and its rival Pfizer are testing "bivalent" shots which mixes each company's original vaccine with an updated omicron version. . As a result, Moderna and its rival Pfizer are testing "bivalent" shots which mixes each company's original vaccine with an updated omicron version. . Moderna's bivalent shot reportedly includes 32 variant mutations of the coronavirus. Studies on the new bivalent shots are currently underway in the United States and Britain. . Results from the studies are expected by late June

Credit: Wibbitz Top Stories    Duration: 01:30Published
Booster Shots in Children Ages 5–11 Increase Omicron Antibodies, Pfizer Says [Video]

Booster Shots in Children Ages 5–11 Increase Omicron Antibodies, Pfizer Says

Booster Shots in Children Ages 5–11 , Increase Omicron Antibodies, Pfizer Says. NBC News reports a booster shot of the Pfizer-BioNTech coronavirus vaccine increases antibody protection in children ages 5-11, the company said on April 14. NBC News reports a booster shot of the Pfizer-BioNTech coronavirus vaccine increases antibody protection in children ages 5-11, the company said on April 14. Given half a year after the initial series of two doses, a booster shot of the Pfizer-BioNTech vaccine increased antibody levels sixfold. In Pfizer's clinical trial, 140 children ages 5 through 11 received a booster shot. According to NBC News, data has not yet been made available to independent researchers for review. In the era of Omicron, booster doses of COVID vaccines have been hit and miss. In adults, a booster dose of Pfizer's vaccine wanes dramatically after four months. Health experts say the same trends are likely to occur in children. For adults, Pfizer's vaccine is 30 micrograms per dose. For children, vaccines are 10 micrograms per dose. Earlier this year, New York Department of Health researchers found Pfizer's vaccine to offer minimal protection against infection in children. But according to NBC, the CDC later said two doses in children offered ample protection against severe infections. But according to NBC, the CDC later said two doses in children offered ample protection against severe infections

Credit: Wibbitz Top Stories    Duration: 01:30Published
Pfizer Issues Recall of Blood Pressure Medication [Video]

Pfizer Issues Recall of Blood Pressure Medication

Pfizer Issues Recall , of Blood Pressure Medication. Pfizer Issues Recall , of Blood Pressure Medication. Pfizer issued a recall of the blood pressure medication Accuretic on March 21. Other versions of the drug are known as hydrochlorothiazide tablets and quinapril. The medications are also used to mitigate the onset of strokes and myocardial infarctions. The recall was issued due to the detection of a cancer-causing carcinogen classified as nitrosamine. This particular nitrosamine is known as N-nitroso-quinapril. According to the Food and Drug Administration (FDA), . nitrosamines are found in a number of common foods and beverages. Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables, FDA, via NPR News. Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables, FDA, via NPR News. Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables, FDA, via NPR News. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time, FDA, via NPR News. Everyone is exposed to some level of nitrosamines, FDA, via NPR News. In issuing the voluntary recall, Pfizer described the potential dangers of ingesting N-nitroso-quinapril for an extended amount of time. Long-term ingestion of N-nitroso-quinapril may be associated with a potential increased cancer risk in humans. , Pfizer, via NPR News. There is no immediate risk to patients taking this medication, Pfizer, via NPR News

Credit: Wibbitz Top Stories    Duration: 01:30Published

BioNTech BioNTech German biotechnology company


COVID-19 COVID-19 Contagious disease caused by SARS-CoV-2

Covid-19 in North Korea: Military ramps up response effort as virus surges [Video]

Covid-19 in North Korea: Military ramps up response effort as virus surges

Credit: FRANCE 24 English    Duration: 01:32Published
Covid-19 update: India logs 1,569 new cases and 19 deaths in last 24 hours | Oneindia News [Video]

Covid-19 update: India logs 1,569 new cases and 19 deaths in last 24 hours | Oneindia News

According to the Union Health ministry's data, India added 1,569 Covid cases and 19 Covid-related deaths in the last 24 hours. #CovidIndia #Covid19 #CovidCases #CoronaDeaths

Credit: Oneindia    Duration: 01:35Published

Covid-19: India reports 1,569 new cases, 19 deaths in last 24 hours; active cases today 16,400

India's active case tally now stands at 16,400, seeing a dip of 917 cases from the previous day, the Union health ministry bulletin stated. The current recovery..
IndiaTimes

Covid vaccination: Price of Corbevax dose reduced from Rs 840 to Rs 250

Corbevax is currently being administered to children in the age group of 12-14.
DNA

Covid 4th wave scare: India logs 2,202 new cases, minor rise in daily infection rate

India continued to witness a dip in the new COVID cases, as the country reported 2,202 fresh infections in the last 24 hours, according to the Union Ministry of..
DNA

You Might Like


Related videos from verified sources

Health Experts Worry Biden’s Plan To Distribute 500 Million COVID-19 Tests Isn’t Enough [Video]

Health Experts Worry Biden’s Plan To Distribute 500 Million COVID-19 Tests Isn’t Enough

Health Experts Worry Biden's Plan, To Distribute 500 Million, COVID-19 Tests Isn't Enough. Health Experts Worry Biden's Plan, To Distribute 500 Million, COVID-19 Tests Isn't Enough. As the Omicron..

Credit: Wibbitz Top Stories     Duration: 01:30Published
COVID-19: the United States Sets Daily High for Infections [Video]

COVID-19: the United States Sets Daily High for Infections

COVID-19: the United States , Sets Daily High for Infections. Politico reports on Dec. 28, the United States set a record for its highest total of new daily COVID-19 infections. 441,278 new..

Credit: Wibbitz Top Stories     Duration: 01:30Published
Omicron Infection Could Increase Immunity to Delta Variant, Study Suggests [Video]

Omicron Infection Could Increase Immunity to Delta Variant, Study Suggests

Omicron Infection Could , Increase Immunity to Delta Variant, Study Suggests. A new study from health officials in South Africa suggests an Omicron COVID-19 infection could increase one's immunity to..

Credit: Wibbitz Top Stories     Duration: 01:30Published

Related news from verified sources

COVID: New Zealand man probed for having 10 vaccine shots


Indian Express Also reported by •newKerala.com

India should emerge as world leader in post COVID New World Order, says PM Modi


newKerala.com

Kolkata: Seniors most at risk, need immediate 3rd shot, say doctors

The 60-plus population remains the most vulnerable to Covid — especially when a new variant like Omicron is on the prowl — and needs a third ‘precaution’...
IndiaTimes Also reported by •newKerala.com